ISCO - International School of Clinical Oncology
A

Novel Therapies and Combinations in Ovarian Cancer

By ISCO - International School of Clinical Oncology FEATURING Alexandra Leary
By ISCO - International School of Clinical Oncology FEATURING Alexandra Leary
386 views
June 7, 2023
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
27:04
Fengting Yan

Cancer Screening Molecular Tools

06:07
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Key Updates in Gynecological Cancers"

Feat. M. Raza Mirza
06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
06:50
Fengting Yan

Year in Review: Ovarian Cancer

11:15
Total Health

2024 Updates in Ovarian Cancer

Feat. T. Tillmanns
25:10
Yale School of Medicine

Ovarian Cancer Prevention and Early Detection - Ovarian Cancer Does …

Feat. M. Minkin, E. Ratner
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
06:23
Total Health

Recent Highlights in Ovarian Cancer

Feat. B. Slomovitz
15:14
Brian Slomovitz

Update in Vulvar and Vaginal Cancer

28:11
OncoAlert

Ovarian Cancer: Setting a New Standard of Care

Feat. M. Raza Mirza
18:16
Insights from 2024 ESGO Annual Meeting

ESGO 2024 Insights: "Antibody-Drug Conjugates in Ovarian Cancer…

Feat. J. Kurtz
23:35
Kathleen Moore

How to Select the Best Maintenance Treatment in Patients With Ovaria…

05:32
Insights from 2023 ESMO Asia Annual Meeting

LARA Trial: Preliminary Efficacy of Pembro + Lenvatinib in Recurrent…

Feat. N. Ngoi
09:42
Erin Crane

Niraparib as 1L Maintenance Treatment for Advanced Ovarian Cancer

05:09
Insights from 2024 SGO Annual Meeting

SGO 2024 Insights: "Final OS Data of Relacorilant, a Selective …

Feat. N. Colombo
10:27
Robert McBane

2023 ISTH Insights: "The EVE Trial - Extending VTE Secondary Pr…

08:37
Fred Hutchinson Cancer Center

Niraparib as 1L Maintenance Treatment for Advanced Ovarian Cancer: D…

Feat. K. Banda
17:06
Ovarian Cancer Midwest Focus, University of Minnesota

Novel ADCs in Ovarian Cancer: A New Treatment Modality

Feat. S. Lheureux
12:21
Insights from 2024 ESGO Annual Meeting

ESGO 2024 Insights: "PARP Inhibitor Resistance Mechanisms in Gy…

Feat. V. Heinzelmann-Schwarz
08:19
Insights from 2023 ESGO Annual Meeting

ESGO 2023 Insights: "Final OS and Long-Term Safety in the ENGOT…

Feat. M. Raza Mirza